Genprex Inc (NAS:GNPX)

$ 1.9 -0.01 (-0.52%) Market Cap: 3.99 Mil Enterprise Value: -4.23 Mil PE Ratio: 0 PB Ratio: 0.42 GF Score: 31/100

Genprex Inc Global One Media Interview Transcript
Jun 22, 2023
Genprex Inc at Sidoti & Company May Micro-Cap Virtual Conference Transcript
May 11, 2023
Genprex Inc KOL Event: Novel Gene Therapy to Treat Type 1 Diabetes Transcript
Apr 12, 2023
Genprex Inc at LD Micro Main Event Transcript
Oct 26, 2022
Genprex Inc at H C Wainwright Global Investment Conference (Virtual) Transcript
Sep 12, 2022
Genprex Inc at LD Micro Invitational Conference (Virtual) Transcript
Jun 08, 2022
Genprex Inc at Noble Capital Markets Investor Conference (Virtual) Transcript
Apr 20, 2022
Genprex Inc at Benzinga Healthcare Small Cap Conference (Virtual) Transcript
Sep 29, 2021
Genprex Inc C-Suite Interview with Noble Capital Markets Transcript
Apr 22, 2021
Cell and Gene Meeting on Mesa - Genprex Transcript
Jan 08, 2021
Genprex launches new branding for its lead drug REQORSA in preparation for upcoming studies Transcript
Nov 06, 2020
Genprex (GNPX) Virtual Road Show with CEO Rodney Varner Transcript
Sep 15, 2020
Genprex (GNPX) Channelchek C-Suite Series, CEO Rodney Varner interview with Noble's Dr. Ahu Demir Transcript
Aug 04, 2020

Cell and Gene Meeting on Mesa - Genprex Transcript

Jan 08, 2021 / NTS GMT

Release Date Price: $150.8 (-2.84%)

Transcript

Michael Redman Genprex

Inc. - EVP & CEO

Hello. My name is Michael Redman. I am the Executive Vice President and Chief Operations Officer of Genprex. We're a gene therapy company headquartered in Austin, Texas.

I may be making forward-looking statements in my presentation today. You're probably familiar with the Safe Harbor statement. And before you make any decision related to the company, please review this information.

Genprex offers new gene therapies that have the potential to change the treatment paradigm of major diseases like lung cancer and diabetes. We are focused on combination trials with blockbuster drugs. We believe we have validation because our recent fast track designation with our lead drug.

Genprex will continue to evaluate new technologies, new therapies, new indications, and always welcome new partners. The focus in 2021 will be to evaluate our lead drug, GPX-001, with the top two lung cancer drugs, Tagrisso and Keytruda. We believe our drug could be additive or synergistic due to the data that we found in our preclinical studies and also with our Phase 1

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.